An algorithm for the evaluation and management of red, yellow, and green zone patients during a botulism mass casualty incident
DOI:
https://doi.org/10.5055/ajdm.2009.0030Keywords:
botulism, botulism algorithm, botulism-induced MCI, mass casualty incident, botulism managementAbstract
Botulinum toxin is one of the most toxic substances known to humankind. It is one among the six Category A agents in the CDC bioterrorism lexicon. This suggests that, while the possibility of a botulism mass casualty incident (MCI) is remote, its unique acute and long-term ramifications must be addressed and planned for. However, an in-depth knowledge of the disease and its tactical management in the acute MCI phase is inconsistent or superficial among healthcare personnel. Therefore, an algorithm has been developed to assist first receivers with the initial management of multiple probable and potential botulism patients when equipment resources are strained and when expert personnel are not readily available. The algorithm is specifically structured to assist with the identification and management of potential respiratory deterioration of suspected botulism patients.References
Centers for Disease Control and Prevention: Bioterrorism Agents/Diseases, A to Z by Category. Available at www.bt.cdc.gov/agent/agentlist-category.asp. Accessed June 3, 2009.
Arnon SS, Schlecter R, Ingelsby D, et al.: Botulinum toxin as a biological weapon. JAMA. 2001; 285: 1059-1070.
Dembek ZF, Smith LA, Rusnak JM: Botulism: Cause, effects, diagnosis, clinical and laboratory identification, and treatment modalities. Disaster Med Public Health Prep. 2007; 1(2): 122-134.
Villar RG, Elliot SP, Davenport KM: Botulism: The many faces of botulinum toxin and its potential for bioterrorism. Infect Dis Clin North Am. 2006; 20(2): 313-327.
Koirala J, Basner S: Botulism, botulinum toxin, and bioterrorism: Review and update. Infect Med. 2004; 21: 284-290.
Botulism: Current, comprehensive information on pathogenesis, microbiology, epidemiology, diagnosis, and treatment. Available at http://www.cidrap.umn.edu/cidrap/content/bt/botulism/biofacts/botulismfactsheet.html. Accessed June 7, 2009.
Taillac PP, Kim J: CBRNE – Botulism.Available at http://emedicine.medscape.com/article/829125-overview. Accessed June 7, 2009.
Stankovic C, Mahajan P,Ye H, et al.: Bioterrorism: Evaluating the preparedness of pediatricians in Michigan. Pediatr Emerg Care. 2009; 25(2): 88-92.
Chen FM, Hickner J, Fink KS, et al.: On the front lines: Family physicians’ preparedness for bioterrorism. J Fam Pract. 2002; 51(9): 745-750.
Alexander GC, Larkin GL,Wynia MK: Physicians’ preparedness for bioterrorism and other public health priorities. Acad Emerg Med. 2006; 13(11): 1238-1241.
Iserson KV, Heine CE, Larkin GL, et al.: Fight or flight: The ethics of emergency physician disaster response. Ann Emerg Med. 2008; 51: 345-353.
Lerner EB, Schwartz RB, Coule PL, et al.: Mass casualty triage: An evaluation of the data and development of a proposed guideline. Disast Med Pub Health Prep. 2008; 2(Suppl 1): S25-S34.
Patocka J, Splino M, Merka V: Botulism and bioterrorism: How serious is it? Acta Medica *Hradec Kralove. 2005; 48(1): 23-28.
Bedlak RS, Sanders DB: How to handle myasthenic crisis. Postgrad Med. 2000; 107: 211-222.
Tseng BS, Markowitz JA: Guillain-Barrè syndrome in childhood. Available at http://emedicine.medscape.com/article/1180594-overview. Accessed June 7, 2009.
Green DM:Weakness in the ICU: Guillain-Barrè, myasthenia gravis, and critical illness polyneuropathy/myopathy. Neurologist. 2005; 11: 338-347.
Mehta S: Neuromuscular disease causing acute respiratory failure. Resp Care. 2006; 51: 1016-1021.
Fulgham JR,Wijdicks EFM: Guillain-Barrè syndrome. Crit Care Clin. 1997; 13(1): 1-15.
Orenstein DM, Holt LS, Rebovich P, et al.: Measuring ease of breathing in young patients with cystic fibrosis. Ped Pulmon. 2002; 34(6): 473-477.
Jain VK, Behari S: Management of atlanto-axial dislocation: Some lessons learned. Neurol India. 2002; 50(4): 386-397.
Yavagal DR, Mayer SA: Respiratory complications of rapidly progressive neuromuscular syndromes: Guillain-Barrè syndrome and myasthenia gravis. Semin Respir Crit Care Med. 2002; 23(2): 221-229.
Van Rynen JL, Rega PP, Budd C, et al.: The use of negative inspiratory force by ed personnel to monitor respiratory deterioration in the event of a botulism-induced MCI. J Emerg Nurs. 2009; 35(2): 114-117.
Rega P, Bork C, Burkholder-Allen K, et al.: The single-breathcount test as an adjunct in triage during a botulism mass-casualty incident. Prehosp Disaster Med. 2009 (in press).
Van Rynen JL, Rega PP, Budd C, et al.: The use of negative inspiratory force by ed personnel to monitor respiratory deterioration in the event of a botulism-induced MCI. J Emerg Nurs. 2009; 35(2): 114-117.
Mace SE: Challenges and advances in intubation: Airway evaluation and controversies with intubation. Emerg Med Clin N Am. 2008; 26: 977-1000.
Botulism Antitoxin Bivalent (Equine) Types A and B Product Insert. Avilable at http://botulismtoolkit.com/wp-content/media/botulismab.pdf. Accessed July 17, 2009.
BabyBIG®, Botulism immune globulin intravenous (human) (BIG-IV) product insert (2003). Available at http://botulismtoolkit.com/?page_id=56. Accessed July 17, 2009.
Clinical pathway: Botulism. Center for Infectious Disease Research and Policy. Available at www.cidrap.umn.edu/cidrap/files/19/botulism_clinical_pathway.pdf. Accessed July 17, 2009.
Botulism. Infectious Disease Epidemiology Section, Office of Public Health, Louisiana Department of Health and Hospitals. Revised April 20, 2009.
Published
How to Cite
Issue
Section
License
Copyright 2007-2023, Weston Medical Publishing, LLC
All Rights Reserved
